Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Common Equity (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Common Equity for 4 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 27.1% to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a 27.1% decrease, with the full-year FY2024 number at $4.0 million, down 17.57% from a year prior.
  • Common Equity was $4.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $2.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $7.1 million in Q1 2024 to a low of -$24.7 million in Q2 2023.
  • A 4-year average of -$5.1 million and a median of $3.5 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 133.34% in 2024, then tumbled 43.46% in 2025.
  • 60 Degrees Pharmaceuticals' Common Equity stood at -$24.1 million in 2022, then surged by 119.87% to $4.8 million in 2023, then fell by 17.57% to $4.0 million in 2024, then rose by 9.91% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Common Equity are $4.3 million (Q3 2025), $2.3 million (Q2 2025), and $4.0 million (Q1 2025).